Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort

It has been proposed that rare variants within the double strand break repair genes CHEK2, BRIP1 and PALB2 predispose to breast cancer. The aim of this study was to evaluate the prevalence of these variants in an Irish breast cancer cohort and determine their contribution to the development of breast cancer in the west of Ireland. We evaluated the presence of CHEK2_1100delC variant in 903 breast cancer cases and 1,016 controls. Six previously described variants within BRIP1 and five within PALB2 were screened in 192 patients with early-onset or familial breast cancer. Where a variant was evident, it was then examined in the remainder of our 711 unselected breast cancer cases. CHEK2_1100delC was found in 5/903 (0.5%) breast cancer cases compared to 1/1016 (0.1%) controls. One mutation at BRIP1 (2392 C>T) was identified in the early-onset/familial cohort. Examination of this variant in the remainder of our cohort (711 cases) failed to identify any additional cases. None of the previously described PALB2 variants were demonstrated in the early-onset/familial cohort. We show evidence of CHEK2_1100delC and BRIP1 2392 C>T within the Irish population. CHEK2_1100delC and BRIP1 mutations incidence in Ireland is similar to that found in other unselected breast cancer cohorts from northern European countries. We found no evidence to suggest that PALB2 mutation is an important breast cancer predisposition gene in this population.

[1]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[2]  R. Wilkins.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[3]  A. Spurdle,et al.  Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer , 2005, Breast Cancer Research.

[4]  W. Chen,et al.  Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: Not present in the Chinese familial breast cancer population , 2008, Advances in therapy.

[5]  Alfons Meindl,et al.  BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study , 2007, BMC Cancer.

[6]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[7]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[8]  J. Palmgren,et al.  Linkage Disequilibrium Mapping of CHEK2: Common Variation and Breast Cancer Risk , 2006, PLoS medicine.

[9]  J. Struewing,et al.  Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes , 2004, BMC Cancer.

[10]  A. Jakubowska,et al.  A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland , 2007, Breast Cancer Research and Treatment.

[11]  B. Ponder,et al.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[12]  J. Simard,et al.  Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families , 2008, Journal of Human Genetics.

[13]  M. Jobling,et al.  Y-chromosome variation and Irish origins , 2000, Nature.

[14]  W. Foulkes,et al.  Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.

[15]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[16]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[17]  J. Benítez,et al.  The breast cancer low‐penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population , 2004, International journal of cancer.

[18]  Z. Shao,et al.  The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.

[19]  B. Sobhian,et al.  A Novel Breast Cancer–Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function , 2008, Clinical Cancer Research.

[20]  A. Pérez-Lezaun,et al.  Absence of CHEK2 mutations in Spanish families with hereditary breast cancer. , 2005, Cancer genetics and cytogenetics.

[21]  J. Hopper,et al.  Penetrance Analysis of the PALB2 c.1592delT Founder Mutation , 2008, Clinical Cancer Research.

[22]  S. Plon.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2010 .

[23]  Douglas F. Easton,et al.  Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer , 2007, PloS one.

[24]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. V. Rensburg,et al.  PALB2 sequence variants in young South African breast cancer patients , 2009, Familial Cancer.

[26]  D. Ilencikova,et al.  The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic , 2005, Breast Cancer Research and Treatment.

[27]  H. Nevanlinna,et al.  BACH1 Ser919Pro variant and breast cancer risk , 2006, BMC Cancer.

[28]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[29]  Petra M. Nederlof,et al.  Analysis of PALB2/FANCN-associated breast cancer families , 2007, Proceedings of the National Academy of Sciences.

[30]  Nazneen Rahman,et al.  Genetic predisposition to breast cancer: past, present, and future. , 2008, Annual review of genomics and human genetics.

[31]  S. Bojesen,et al.  Increased risk of breast cancer associated with CHEK2*1100delC. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Z. Shao,et al.  Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.

[33]  H. Thierens,et al.  Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation. , 2005, Cancer genetics and cytogenetics.

[34]  N. Miller,et al.  Low penetrance breast cancer predisposition SNPs are site specific , 2009, Breast Cancer Research and Treatment.

[35]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[36]  Jinghui Zhang,et al.  Mutational analysis of the BRCA1‐interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2‐negative probands from breast‐ovarian cancer families and among early‐onset breast cancer cases and reference individuals , 2003, Human mutation.

[37]  S. Chanock,et al.  Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses , 2006, Human Genetics.

[38]  M. Urioste,et al.  Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families , 2009, Breast Cancer Research and Treatment.

[39]  H. Boezen,et al.  No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors. , 2005, European journal of cancer.

[40]  E. Gillanders,et al.  Evidence against PALB2 involvement in Icelandic breast cancer susceptibility , 2008, Journal of Negative Results in Biomedicine.

[41]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[42]  H. Wichmann,et al.  German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. , 2005, European journal of cancer.